Previous 10 | Next 10 |
home / stock / lbtsf / lbtsf news
The following slide deck was published by Almirall, S.A. in conjunction with their 2021 Q2 earnings call. For further details see: Almirall, S.A. 2021 Q2 - Results - Earnings Call Presentation
Almirall, S.A. (LBTSF): 1H Normalised net income of €57.8MRevenue of €415.5M (-4.0% Y/Y) misses by $81.18M.The company is upgrading its Core EBITDA Guidance for 2021 to €195 MM - €215M (previously €190 MM-€210M)Press Release For further details see:...
Almirall delivers robust H1 performance and increases full-year guidance - Robust business performance with significant growth in Core EBITDA: Core Net Sales €415.5 MM (+8% year-on-year) and Core EBITDA reached €125.6 MM, (+40.4% year-on-year) - The company is ...
Almirall receives European Commission approval of Klisyri® (tirbanibulin), an innovative topical treatment for actinic keratosis - Klisyri® (tirbanibulin) is a topical first-in-class microtubule inhibitor indicated for the treatment of actinic keratosis (AK) of the fac...
Almirall receives positive CHMP opinion for Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) of the face or sca...
The following slide deck was published by Almirall, S.A. in conjunction with their 2021 Q1 earnings call. For further details see: Almirall, S.A. 2021 Q1 - Results - Earnings Call Presentation
Almirall SA. (LBTSF) Q1 2021 Earnings Conference Call May 10, 2021, 04:00 AM ET Company Participants Pablo Divasson - Head, IR & CEC Jorge Ballart - Chairman, PD Carlos Gallardo - VC & PD Gianfranco Nazzi - CEO Michael McClellan - EVP, Finance & CFO Conference Call Participants Ja...
Almirall's solid core business Q1 performance boosted by Growth drivers momentum - Good business performance with significant growth in Core EBITDA: Core Net Sales €215.4 MM (+5% year-on-year) and Core EBITDA €68.0MM (+46% year-on-year) - Growth drivers momentu...
Almirall, S.A. (LBTSF): FY normalized Net Income of €95.1MRevenue of €814.5M (-10.3% Y/Y)Press Release For further details see: Almirall, S.A. reports FY results
Almirall's 2020 Full-Year Results Almirall delivers on latest 2020 guidance and sets growth targets for 2021 PR Newswire BARCELONA, Spain , Feb. 22, 2021 /PRNewswire/ -- The company delivered on its latest guidance despite a challenging year impacted ...
News, Short Squeeze, Breakout and More Instantly...
Almirall Sa Ord Company Name:
LBTSF Stock Symbol:
OTCMKTS Market:
Almirall’s sustainability strategy focuses on five pillars: Planet, People, Patients, Partners and Principles defining clear targets and measurements Among other commitments, Almirall aims to – by 2030 - reduce absolute direct greenhouse gas emissions by 50%, minimize the ge...
Almirall presented the interim Week 52 results of the POSITIVE clinical study at the IFPA Conference 2024, showing the benefits of the effective treatment with Ilumetri (tildrakizumab) in patients with moderate to severe psoriasis achieving improvement of physical symptoms and overall wellbeing. ...
Positive trajectory with Net Sales increase by 6.6% to a total of €247.4 MM, EBITDA increase of 1.4% YoY to a total of €52.5 MM driven by higher overall sales Performance driven by biologics as key growth engines, with Ilumetri ® showing 30% increase in sales vs Q1 ...